No Data
Medical stocks collectively surged! Bullish news has arrived, the medical sector welcomes a catalyst.
The medical sector with lagging growth finally sees a catalyst! Analysis believes that for medical institutions, prepayment of medical insurance funds helps optimize and improve the daily operation cash flow and financial pressure of medical institutions, reducing the potential receivables and bad debt risks caused by unpaid medical insurance expenses. For medical insurance, it enhances the settlement efficiency and encourages the active diagnosis and treatment enthusiasm of medical institutions.
Multiple bullish factors boost pharmaceutical stocks listed in Hong Kong, institutions say they still face this risk in the short term.
①What are the policy measures to support the field of innovative drugs? ②What unfavorable effects on domestic pharmaceutical stocks might Trump's election bring about?
Hong Kong stocks anomalies | Medical device stocks rise, medical insurance prepayments expected to accelerate enterprise receivables, innovative devices will usher in a new volume of space.
Most medical instruments stocks are rising. As of the time of publication, Microport (00853) is up 5.01% at 6.92 Hong Kong dollars; Sh Pharma (02607) is up 4.05% at 13.36 Hong Kong dollars; Sinopharm (01099) is up 3.14% at 21.35 Hong Kong dollars.
Hong Kong stocks have seen unusual movements, with CRO concept stocks generally under pressure. The emotions are influenced by the results of the USA election. Institutions point out that the probability of the Biosecurity Law being an independent law may
CRO concept stocks are generally under pressure. As of the time of publication, GenScript Biotech (01548) fell by 6.68% to HKD 10.9; Viva Biotech (01873) fell by 3.16% to HKD 0.92; Pharmaron (03759) fell by 2.64% to HKD 16.22.
Express News | Gilead has signed multiple cooperation agreements with China National Pharmaceutical Group, Shanghai Pharmaceuticals, and others.
Sinopharm (1099.HK): Medical device sector under pressure, looking forward to stable operation in 2025.
Core viewpoint On October 28, the company released the performance report for the third quarter of 2024. In the first three quarters of 2024, the company achieved revenue of 442.423 billion yuan, a year-on-year decrease of 0.78%, and achieved a net profit attributable to shareholders of 5 billion yuan.
No Data
No Data